Anti mek1 2 4694

The EGFR inhibitor Erlotinib, IGF1R inhibitor NVP-AEW541, ERK 1/2 inhibitor PD184352 and mTOR inhibitor Rapamycin (Sirolimus) were all purchased from Selleck Chemicals (California, USA). Drugs were dissolved in DMSO at recommended concentration and stored at −20°C, and diluted in culture medium respectively with <0.1% concentration of DMSO. EGF and IGF1 were purchased from Sino Biological Inc. (Beijing, China), and dissolved in water with final concentration at 100 and 50μg/L, respectively. All primary antibodies used were purchased from Cell Signaling Technology (Boston, USA), which included anti phospho-EGFR^Tyr1068#3777, anti EGFR#2085, antiphospho-IGF1Rβ^Tyr1316#6113, antiIGF1Rβ #9750, antiphspho-MEK1/2^Ser217/221 #9154, anti MEK1/2 #4694, antiphospho-Erk1/2^{Thr202/Tyr204} #8201, antiErk1/2 #9102, antiphospho-Akt^Ser473 #4060, anti Akt#4691, antiphospho-mTOR^Ser2448 #5536 and anti mTOR #2983 antibodies.